ArticleTrials2020

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.

Shuo Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.